Baird analyst Colleen Kusy raised the firm’s price target on Cogent Biosciences (COGT) to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its model following the release of SUMMIT data in Non-AdvSM which was better than the worst case scenarion but worse than the best case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Promising Outlook for Cogent Biosciences: Bezuclastinib’s Potential in Systemic Mastocytosis and Beyond
- Cogent Biosciences Receives Buy Rating on Promising Trial Results and Market Potential
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
- Cogent Biosciences price target raised to $18 from $16 at Leerink
- Cogent Biosciences price target raised at Jefferies after ‘home run’ data